docetaxel

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

docetaxel
Oct 23, 2024, 15:44 | Drugs
FDA approves Novocure’s treatment for mNSCLC
The FDA has granted approval for Novocure's Optune Lua as a treatment option for metastatic…
Oct 19, 2024, 15:57 | Insight
FDA Approves Tumor Treating Fields for Advanced NSCLC: Insights from the LUNAR Trial
The FDA has approved tumor treating fields (TTFields; Optune Lua) in combination with docetaxel or…
Oct 10, 2024, 03:18 | Insight
Paper Alert: Oral Dexamethasone Enhances Efficacy of Docetaxel-Ramucirumab Therapy in Previously Treated Lung Cancer: A Retrospective Analysis
A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab…
Sep 26, 2024, 15:35 | Blog
Jarushka Naidoo: TL01 Phase III Datopotamab-Deruxtecan vs Docetaxel in second-line NSCLC
Jarushka Naidoo shared a post on X, about recent paper published in Journal of Clinical…
Sep 18, 2024, 23:30 | Blog
Sami Mansfield: Implementing the Six Pillars of lifestyle medicine to improve cancer outcomes
Sami (Papacek) Mansfield posted the following on LinkedIn: “This weekend I rounded up another lap…
Sep 14, 2024, 09:48 | Insight
Aleix Prat: Reveal Genomics Announces Positive Top-line Results for HER2DX in CLEOPATRA Phase III Trial
Aleix Prat, Director of Cancer Institute and Blood Disorders at Hospital Clínic de Barcelona, shared…
Sep 13, 2024, 19:00 | Blog
Brian Shields discusses TROPION-Lung01 Clinical Trial and AI’s role in content curation
Brian Shields, Creator of KOL Pulse AI, posted the following on LinkedIn: “One of the…
Sep 12, 2024, 09:57 | Insight
Meta-analysis of 20 RCTs with 14,995 Metastatic Castrate-sensitive Prostate Cancer patients
Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at Dana-Farber Cancer Institute, shared…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 10, 2024, 13:45 | Societies
Rami Manochakian's key highlights from WCLC24
WCLC is a major international event focused on the latest advancements in lung cancer research,…
Jul 12, 2024, 16:05 | Insight
Piotr Wysocki: Bone Pain and Survival Among Patients With mHSPC
Piotr Wysocki recently posted on LinkedIn: "Bone pain is linked to worse overall survival (OS) in…
Jul 1, 2024, 14:03 | Drugs
Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients - Sarah Cannon Research Institute
Sarah Cannon Research Institute shared on LinkedIn: "Significant advancements in NSCLC treatment! SCRI's Dr. Robert Jotte…
Jun 22, 2024, 05:04 | Blog
Yüksel Ürün: Carboplatin plus docataxel for patients with biallelic HRR gene alterations in metastatic castration-resistant prostate cancer
Yüksel Ürün shared a post on X: “The ABCD Trial shows promising results with carboplatin…
Jun 15, 2024, 12:39 | Insight
Docetaxel versus paclitaxel in black patients with breast cancer
The American Society of Clinical Oncology (ASCO) shared a post on X: “ICYMI from ASCO24:…
Jun 13, 2024, 13:34 | Insight
Stephen Liu: Report on brain metastases in patients with KRAS NSCLC
Stephen Liu shared on X/Twitter: "Report on brain metastases in patients with KRAS NSCLC in phase…
Jun 5, 2024, 12:51 | Blog
Susan G. Komen: Tarah Ballinger presents results from the EAZ171 trial at ASCO24
Tarah Ballinger, Assistant Professor of Clinical Medicine at Indiana University School of Medicine, shared a…
Jun 3, 2024, 22:53 | Insight
Paul Healy: AstraZeneca and Daiichi Sankyo have announced positive results from datopotamab deruxtecan in certain lung cancer patients
Paul Healy, Director of PHARMeMED, shared on LinkedIn: "AstraZeneca (AZ) and Daiichi Sankyo have announced positive…
Jun 3, 2024, 13:08 | Insight
Gilberto Lopes: In phase 3 EVOKE-01 study improvement of OS was noted in patients without response to prior IO
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
Jun 3, 2024, 11:57 | Societies
Tanja Obradovic: Very dynamic day at ASCO2024
Tanja Obradovic shared a post on LinkedIn: "Very dynamic ASCO2024 day as we learned quite…
Jun 2, 2024, 09:09 | Societies
15 Posts From ASCO24 Day 2 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
May 31, 2024, 07:46 | Blog
Shushan Hovsepyan: Sarcoma Sessions at ASCO2024!
Shushan Hovsepyan shared a post on LinkedIn: “Sarcoma Sessions at ASCO2024!   SARC037: Phase II results…
May 28, 2024, 14:25 | Insight
Luis E. Raez: Sometimes new agents don't have a better OS but they provide benefits
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Stephen Liu on…
May 27, 2024, 04:19 | Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
May 9, 2024, 06:45 | Insight
Piotr Wysocki: Neoadjuvant chemo-hormonal therapy before prostatectomy: First randomized study
Piotr Wysocki recently posted on LinkedIn: "Qian H et al. conducted a randomized clinical trial (phase…
May 5, 2024, 12:04 | Blog
Piotr Wysocki: Elective Pelvic Lymph Node Radiation for elderly patients with prostate cancer
Piotr Wysocki recently shared on LinkedIn: "Sayan M et al. analyzed individual patient data from a…
Apr 19, 2024, 20:03 | Insight
Piotr Wysocki: BRCA1/2 mutations represent a poor prognostic factor for mCRCP patients - underscoring the need to use PARPi as soon as possible
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 15, 2024, 14:41 | Drugs
Piotr Wysocki: The [177Lu]Lu-PSMA-617 plus enzalutamide combination is active and safe in mCRPC patients, but is it really an option for first-line treatment?
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 12, 2024, 10:05 | Drugs
Piotr J. Wysocki: Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…
Apr 6, 2024, 07:14 | Drugs
Antonio Passaro: Why is this press release of Bristol Myers Squibb so crucial for our community?
Antonio Passaro, Medical Director at the Institute of European Oncology (IEO), shared a post on…
Feb 23, 2024, 18:07 | Insight
Estela Rodriguez: Great session on ADCs for lung cancer at WCLC24
Estela Rodriguez recently tweeted: "Saving the best for last! Great session on ADCs for lung…
Dec 29, 2023, 15:40 | Insight
Balazs Halmos: The docetaxel enigma continues
Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center, shared a post…
Dec 10, 2023, 16:59 | Insight
Yüksel Ürün: MFS continues to be a reliable predictor for overall survival
Yüksel Ürün, Medical Oncologist at Ankara University, shared on X: “With better access to docetaxel…
Oct 7, 2023, 18:27 | Opinion
Bishal Gyawali: This offers a good lesson on why oncology KOLs are not always the best person to interpret the results of a trial.
Quoting Bishal Gyawali, Associate Professor at Queen’s University, on LinkedIn: “This is from FDA’s ODAC…
All: 33 Posts: 1 - 100
Special Coverage